Cardiorenal disturbances in perimenopausal women

Aim. To identify early signs of renal dysfunction; to investigate the associations between renal function and vascular remodelling; to evaluate the role of metabolic and hydrodynamic disturbances in the development of cardiorenal syndrome among perimenopausal women; and to assess the potential of hormone replacement therapy (17β-estradiol 1 mg and drospirenone 2 mg) for the correction of the above-mentioned disturbances.
Material and methods. In total, 69 perimenopausal women were divided into two groups. Group I included 69 premenopausal women, while Group II consisted of 43 women in early postmenopause. Mean age in Group I was 49,0 years (95% CI 48,0-51,0 years); in Group II, it was 54,0 (50,0-56,0) years (p<0,01). Age at menopause reached 50,3 (48,0-52,0) years, with median duration of menopause of 3,5 (2,0-5,0) years. All participants underwent biochemical blood tests (creatinine (Cr), uric acid (UA), lipid profile, and glucose tolerance test (GTT)). Large elastic artery remodelling was assessed by intima-media thickness (IMT) of common carotid artery (CCA). Non-invasive assessment of endothelial vasoregulatory function involved the measurement of brachial artery (BA) endothelium-dependent vasodilatation (EDVD) in the reactive hyperemia test (RHT). Renal function was assessed by glomerular filtration rate (GFR) and Cr clearance (CrC). Monoalbuminuria (MAU) was qualitatively assessed with a urine strip test. Postmenopausal women were additionally divided into two groups: 23 patients were administered HRT (17β-estradiol 1 mg and drospirenone 2 mg; Angelique medication), while 20 women not receiving HRT comprised a control group. At the end of the study, after 12 months, the assessment of metabolic status, body mass dynamics, endothelial vasoregulatory function, and CCA IMT was repeated.
Results. In most postmenopausal women, lipid and carbohydrate metabolism disturbances were observed, which were typical for metabolic syndrome (MS). Lipid metabolism disturbances were observed as early as in premenopause, but reached their maximum during early postmenopause. Postmenopausal women, compared to their peers in premenopause, had significantly higher fasting and postprandial levels of blood glucose. Structural and functional changes in vascular wall were more severe in postmenopausal vs. premenopausal women (p<0,001). While blood flow velocity in the RHT was comparable in both groups, postmenopausal women did not demonstrate a comparable increase in BA EDVD, in contrast to premenopausal females. This could point to the decrease in BA sensitivity to endothelial shear stress among women in postmenopause. Reduced GFR was observed only in postmenopausal women. MAU was registered in premenopausal women with normal GFR, as well as in postmenopausal females. These data on independent role of MAU and reduced GFR suggest an increase in the proportion of women with subclinical renal injury, as a manifestation of target organ damage.
Conclusion. The associations between vascular structure and function, renal function, and main MS components were demonstrated. HRT (17β-estradiol 1 mg and drospirenone 2 mg) had beneficial effects on BP dynamics, visceral obesity, metabolic status, and arterial structure and function.

1. Wu S., Chou P., Tsai S., et al. The impact of years since menopause on the development of impaired glucose tolerance. J Clin Epidemiol 2001;54:117-20.

2. Toth M.J., Tchernof A., Sites C.K., Poehlman E.T. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000; 24(2):226-31.

3. Podzolkova I.M., Podzolkov V.I., Glazkova O.L. Metabolic syndrome at women: two sides of one problem. Obstetrics and gynecologi 2003; 6:28-33. Russian (Подзолкова И.М., Подзолков В.И., Глазкова О.Л. Метаболический синдром у женщин: две грани одной проблемы. Акуш гинек 2003; 6: 28-33).

4. Brochu M., Starling R.D., Tchernof A., et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab 2000; 85:2378-84.

5. Rendell M., Hulthen U.L., Tornquist C., et al. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001; 86:744-9.

6. Hernandez-Ono A., Monter-Carreola G., Zamora-Gonzalez J., et al. Association of visceral fat with coronary risk factors in population-based sample of postmenopausal women. Int J obes Relat Metab Disord 2001; 26:33-9.

7. Van Pelt R.E., Evans E.M., Schechtman K.B, et al. Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Obes Relat Metab Disord 2001; 25: 1183-8.

8. Lovergrove J.A., Silva KDRR, Wright J.W., Williams C.M. Adiposity, insulin and lipid metabolism in post-menopausal women. Int J Obes Relat Metab Disord 2002; 26:475-86.

9. Atsma F., Bartelink MLEL, Grobbee D.E., et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265-79.

10. Tremollieres F.A., Pouilles J.M., Cauneille C., Ribot С. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 1999; 142(2): 415-23.

11. Anichkov D.F., Shostak N.F., Zhuravleva A.D. Menopause and cardiovascular risk. Rational Pharmacotherapy in Сardiology 2005; 1(1):37-42. Russian (Аничков Д.Ф., Шостак Н.Ф., Журавлева А.Д. Менопауза и сердечно- сосудистый риск. Рационал Фармакотер кардиол 2005; 1(1): 37-42).

12. Carr M. The emergence of metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88:2404-11.

13. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA 2006; 295: 1288-99.

14. Mancia G., Bombelli M., Corrao G., et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage and prognosis. Hypertension 2007; 49: 40-7.

15. Cuspidi C., Valero C., Giudici V., et al. Metabolic syndrome and multiple organ damage in essential hypertension. Blood Press 2008; 17 (4): 195- 203.

16. Dzherieva I.S., Volkova I.N. Arterial hypertension and metabolic disorders. Klin Med. 2010;88(2):4-8. Russian (Джериева И.С., Волкова И.Н. Артериальная гипертензия и метаболические нарушения. Клин мед 2010; 88 (2): 4-8).

17. McDonald S.P., Maguire G.P., Duarte N., et al. Carotid and intimamedia thickness, cardiovascular risk factors and albuminuria in a remote Australian Aboriginal community. Atherosclerosis 2004; 177(2): 423-31.

18. Saginova E.A., Galljamov M.G., Severova M.M., et al. The Role of leptin, adiponectin and insulin-resistance markers in development of early stages of chronic kidney disease and atherosclerosis of carotid arteries in obese patients. Ter Arkh 2011;83(6):47-53. Russian (Сагинова Е.А., Галлямов М.Г., Северова М.М. и др. Роль лептина, адипонектина и маркеров инсулинорезистентности в развитии ранних стадий хронической болезни почек и атеросклероза сонных артерий у больных ожирением. Тер архив 2011;83(6): 47-53).

19. Saginova E.A., Fedorova E.Ju., Fomin V.V., et al. Formation of defeat of kidneys at patients with obesity. Ter Arkh 2006; 78(5):36-41. Russian (Сагинова Е.А., Федорова Е.Ю., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер архив 2006; 78(5): 36-41).

20. Zotova I.V., Zatejwikov D.A., Sidorenko B.A. Synthesis of Nitric Oxide and Development of Atherosclerosis. Kardiologiya 2002;42(4):58-65. Russian (3отова И.В., Затейщиков Д.А., Сидоренко Б.А. Синтез оксида азота и развитие атеросклероза. Кардиология 2002;42(4):58-65).

21. Mendelsohn M., Karas R. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340:1801-11.

22. Veber V.R. Arterial hypertension in postmenopausal women. Serdce 2006; 7(31):346-52. Russian (Вебер В.Р. Артериальная гипертензия у женщин в постменопаузальном периоде. Сердце 2006; 7(31):346-52).

23. McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 2007; 34(7):665-71.

24. Sharipova G.H., Saidova M.A., Balahonova T.V., et al. Affection of target organs in hypertensive patients with and without metabolic syndrome. Ter Arkh 2009; 81(6):67-73. Russian (Шарипова Г.Х., Саидова М.А., Балахонова Т.В и др. Особенности поражения органов-мишеней у больных артериальной гипертонией с наличием и в отсутствие метаболического синдрома. Тер архив 2009; 81(6):67-73).

25. Chambless L.E., Folsom A.R., Clegg L.X., et al. Carotid wall thickness is predictive of incident clinical stroke:ARIC study. Am J Epidemiol 2000; 151:478-87.

26. Ogata T., Yasaka M., Yamagishi M., et al. Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. J Ultrasound Med 2005; 24: 469-74.

27. Moiseev V.S., Kabalava Zh.D. Cardiorenal syndromes (pathogenetic, clinicodiagnostic, prognostic and therapeutic aspects. Ter Arkh 2011; 83 (12): 5-11. Russian (Моисеев В.С., Кабалава Ж.Д. Кардиоренальные синдромы (патогенетические, клинико-диагностические, прогностические и терапевтические аспекты). Тер архив 2011; 83 (12): 5-11).

28. Bondar I.A., Klimontov V.V., Simakova A.I. Obesity and chronic kidney disease. Ter Arkh 2011; 83(6):66-70. Russian (Бондарь И.А., Климонтов В.В., Симакова А.И. Ожирение и хроническая болезнь почек. Тер архив 2011; 83(6):66-70).

29. Muhin N.A., Fomin V.V., Lebedeva M.V. Hyperuricemia as a component of cardiorenal syndrome. Ter Arkh 2011;83(6):5-13. Russian (Мухин Н.А., Фомин В.В., Лебедева М.В. Гиперурикемия как компонент кардиоренального синдрома. Тер архив 2011;83(6):5-13).

30. Muhin N.A. The chosen lectures on internal diseases. M.: Litterra 2006. pp.74-95. Russian (Мухин Н.А. Избранные лекции по внутренним болезням. М.: «Литтера» 2006:74-95).

31. Novikova M.S., Shilov E.M., Borisov V.V. Hyperfiltration is an early sign of evolving chronic renal disease in males with metabolic syndrome. Ter Arkh 2010; 82(4):52-6. Russian (Новикова М.С., Шилов Е.М., Борисов В.В. Гиперфильтрация – ранний признак развития хронической болезни почек у мужчин с метаболическим синдромом. Тер архив 2010; 82(4):52-6).

32. Kobalava Zh.D., Villeval’de S.V., Efremovceva M.A. Independent Diagnostic Value of Microalbuminuria and Glomerular Filtration Rate in Patients With Arterial Hypertension for Detection of Subclinical Renal Involvement. Kardiologiia 2010; 50(4):12-7. Russian (Кобалава Ж.Д., Виллевальде С.В., Ефремовцева М.А. Самостоятельное диагностическое значение микроальбуминурии и расчетной скорости клубочковой фильтрации у больных артериальной гипертонией для выявления субклинического поражения почек. Кардиология 2010; 50(4):12-7).

33. Muhin N.A., Fomin V.V., Saginova E.A., et al. Endotelial dysfunction and defeat of kidneys at obesity. Vestn Ross Akad Med Nauk 2006; 12:25-31. Russian (Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении. Вестн РАМН 2006; 12:25-31).

34. Fomina I.G., Bragina A.E., Gajdamakina N.E., Salimzhanova Ju.N. Renal hemodynamicsandglomerular filtrationrate inmenandwomenwitharterial hypertensionat theageof 40-60 years. Rational Pharmacotherapy in Сardiology 2007; 3(5):69-72. Russian (Фомина И.Г., Брагина А.Е., Гайдамакина Н.Е., Салимжанова Ю.Н. Почечная гемодинамика и клубочковая фильтрация у больных с гипертонической болезнью в возрасте 40-60 лет. Рациональная фармакотер кардиол 2007; 3(5): 69-72).

35. Novikova M.S., Kutyrina I.M., Shilov E.M. Current metods for measuring the glomerular filtration rate in persons with normal weight and overweight. Ter Arkh 2010; 82(3):67-71. Russian (Новикова М.С., Кутырина И.М., Шилов Е.М. Современные методы определения скорости клубочковой фильтрации у лиц с нормальной и избыточной массой тела. Тер архив 2010; 82(3): 67-71).

36. Deanfield J., Donald A., Ferri C., et al. Endothelial function and dysfunction. Part 1: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertension 2005; 23(1): 7-17.

37. Matthews K.A., Meilahn E., Killer L.H. Menopause and risk factors for coronary heart disease. New Engl J Med 1989; 321: 641-6.

38. Van Beresteijn E.C.H., Korevaar J.C., Huijbregts P.C.W. Perimenopausal increase in serum cholesterol: A 10-year longitudinal studi. Am J Epidemiol 1993; 137: 383-92.

39. Da Luz P.L., Favarato D., Faria-Neto Junior J.R., et al. High Ratio of Triglycerides to HDL-Cholesterol Predicts Extensive Coronary Disease. Am J Cardiol 2005; 96:1640-3.

40. Gambacciani M., Pepe А. Vasomotor symptoms and cardiovascular risk. Climacteric 2009; (Suppl 1):32-5.

41. Smetnik V.P., Shestakova I.G. Menopause and cardiovascular system. Ter Arkh 1999; 71(10): 61-5. Russian (Сметник В.П., Шестакова И.Г. Менопауза и сердечно-сосудистая система. Тер архив 1999; 71(10): 61-5).

42. Jakovlev V.M., Jagoda A.V. Яковлев В.М., Ягода А.В. Metabolic syndrome and vascular endothelial. Stavropol’: Stavropol’e; 2008. pp.187- 192. Russian (Метаболический синдром и сосудистый эндотелий. Ставрополь: Ставрополье; 2008: 187-92).

43. Manson J.E., Allison M.A., Rossouw J.E., et al. Estrogen therapy and coronary artery calcification. N Engl J Med 2007; 356: 2591.

44. Jeon G.-Ho, Kim S. H., Yun S.-Ch., et al. Association between serum estradiol level and coronary artery calcification in postmenopausal women. Menopause 2010; 17(5):902-7.

45. Recommendations of experts of Russian scientific cardiologists society for the functional state of buds and prognostication of cardiovascular risk. Cardiovascular Therapy and Prevention 2008; 7(6), suppl. 3. Russian (Рекомендации экспертов Всероссийского научного общества кардиологов по функциональному состоянию почек и прогнозирование сердечно-сосудистого риска. Кардиоваскулярная терапия и профилактика 2008; 7(6), приложение 3).

46. Muhin N.A., Fomin V.V., Moiseev S.V. Microalbuminuria, a universal marcer of unfavourable prognosis. Klin Med 2008; 86(11): 4-9. Russian (Мухин Н.А., Фомин В.В., Моисеев С.В. Микроальбуминурия – универсальный маркер неблагоприятного прогноза. Клин мед 2008; 86(11): 4-9).

47. MCCullough P.A., Li S., Jurkovitz C.T., et al. Keep Investigators. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51(4) Suppl.2: 38-45.

48. Wolf G., Chen S. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1-11.

49. Indraratna P.L., Williams K.M., Graham G.G., Day R.O. Hyperuricemia, cardiovascular disease, and the metabolic syndrome. J Rheumatol 2009; 36(12): 2842-3.

50. Lee J.E., Kim Y.G., Choi Y.H., et al. Serum uric acid is associated with microalbuminuria in prehypertesion. Hypertension 2006; 47(5): 962-7.

51. Chazova I.E., Smetnik V.P., Balan V.E., et al. Consensus of the Russian cardiologists and gynaecologists: conduct of women in peri- and postmenopause with a cardiovascular risk. Consilium medicum 2008; 10(6):258-64. Russian (Чазова И.Е., Сметник В.П., Балан В.Е. и др. Консенсус Российских кардиологов и гинекологов: ведение женщин в перии постменопаузе с сердечно-сосудистым риском. Cons med 2008; 10(6):258-64).

52. Ylikorkala O. Drospirenon-progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms. Climacteric 2005; 8 (suppl):1-3.

53. Tarasova M.A., Jarmolinskaja M.I., Solov’eva O.A., Sahnovskaja M.A. Influence of replaceable therapy 17betta-estradioly in a combination with drospirenony, on dynamics of arterial pressure, endotely-adependent and endotely-independent vasodilatation at women in a postmenopause. Z Acus zen bolezn 2007; LVI(2): 3-8. Russian (Тарасова М.А., Ярмолинская М.И., Соловьева О.А., Сахновская М.А. Влияние заместительной терапии 17В-эстрадиолом в сочетании с дроспиреноном на динамику артериального давления, эндотелий-зависимую и эндотелий-независимую вазодилатацию у женщин в постменопаузе. Ж Акушер жен бол 2007; LVI (2): 3-8.

54. Archer D. Efficacy and safety of drospirenone-estradiol for hormone therapy: a double blind, randomized multicenter trial. Menopause 2005; 12(6):716-27.